Send us a text

For the first time, Surfing NASH takes a deep dive into the prospect of digital therapeutics, their ability to drive outcomes and the critical success factors for proper use and deployment. This is an increasingly apt topic which intermittently surfaces on the podcast but has never featured at the center of conversation. The Surfers are joined by Naim Alkhouri and two new guests with prominent focus in this space: Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics.

In this final session, Roger prompts the panelists to share final thoughts around how digital therapeutics will evolve over time. Each offers a unique perspective accounting for different pieces of a collective puzzle: combating Fatty Liver through technological innovation. Joe and Mark discuss where they envision their respective work to converge. Jörn and Louise offer insights which indicate that different economic structures may require various reimbursement systems and provider dynamics. While this session features ideas around both the enormous potential and daunting challenges behind the world of digital health and digital therapeutics, the panelists provide rich insights which remain optimistic. These are big questions with far-reaching implications for the future of medicine. If you enjoy this topic and would like to learn more, we kindly invite you to leave a review on your preferred listening platform. We also encourage our audience to write us questions to include your on-ground experiences and ideas in the weekly discourse. Thank you for your continued support - stay safe and surf on!